# iOMEDICO AG clinical trials: 53 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 53 trials with iOMEDICO AG as lead sponsor, 14 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by iOMEDICO AG: 53 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/iomedico-ag

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 53
- Recruiting or not yet: 14
- Read on: November 19, 2026

## Trials

The 25 newest of 53, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 4, 2026 | NCT07563595 | Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer | iOMEDICO AG | Observational | Recruiting | Breast Cancer | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07563595) |
| April 30, 2026 | NCT07559799 | A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory... | iOMEDICO AG | Observational | Recruiting | Multiple Myeloma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559799) |
| November 21, 2025 | NCT07240662 | Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma | iOMEDICO AG | Observational | Recruiting | Glioma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07240662) |
| May 16, 2025 | NCT06976918 | Research Platform Myelofibrosis and Anemia | iOMEDICO AG | Observational | Recruiting | Primary Myelofibrosis, Secondary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06976918) |
| January 22, 2025 | NCT06787105 | Fruquintinib in Patients With Metastatic Colorectal Cancer | iOMEDICO AG | Observational | Recruiting | Metastatic Colorectal Cancer (mCRC) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06787105) |
| December 19, 2024 | NCT06743035 | Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly | iOMEDICO AG | Observational | Recruiting | Polycythemia Vera | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06743035) |
| October 1, 2024 | NCT06619275 | Ripretinib (QINLOCK®) According to Current SmPC | iOMEDICO AG | Observational | Completed | GIST - Gastrointestinal Stromal Tumor | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06619275) |
| September 23, 2024 | NCT06607302 | Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an... | iOMEDICO AG | Observational | Recruiting | Cholangiocarcinoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06607302) |
| December 26, 2023 | NCT06181734 | Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC | iOMEDICO AG | Observational | Completed | Acute Myeloid Leukemia (AML) | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06181734) |
| September 21, 2023 | NCT06043011 | Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms | iOMEDICO AG | Observational | Recruiting | Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell... | 2,950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06043011) |
| July 20, 2023 | NCT05954780 | Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma | iOMEDICO AG | Observational | Active not recruiting | Multiple Myeloma | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05954780) |
| August 26, 2022 | NCT05517265 | Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO) | iOMEDICO AG | Observational | Completed | CLL | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05517265) |
| April 13, 2022 | NCT05326308 | Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma | iOMEDICO AG | Observational | Recruiting | Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma | 845 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05326308) |
| March 17, 2022 | NCT05284591 | Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line... | iOMEDICO AG | Observational | Completed | Multiple Myeloma, Newly Diagnosed, Transplant Ineligible, Patient Satisfaction, Patient Preference, Personal... | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05284591) |
| February 24, 2022 | NCT05253911 | Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment... | iOMEDICO AG | Observational | Completed | HER2-positive Breast Cancer | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05253911) |
| November 22, 2021 | NCT05129969 | Registry Platform Ovarian and Endometrial Cancer | iOMEDICO AG | Observational | Recruiting | Ovarian Cancer, Endometrial Cancer, Ovary Neoplasm, Endometrial Neoplasms, Carcinoma, Ovarian, Carcinoma, Neoplasm... | 1,975 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05129969) |
| April 30, 2021 | NCT04867525 | Registry Platform Colorectal Cancer | iOMEDICO AG | Observational | Active not recruiting | Colorectal Cancer Metastatic | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04867525) |
| September 22, 2020 | NCT04557813 | Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion | iOMEDICO AG | Observational | Completed | NTRK Family Gene Mutation | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04557813) |
| August 12, 2020 | NCT04510740 | Liver Cancer Registry Platform | iOMEDICO AG | Observational | Active not recruiting | Hepatocellular Carcinoma (HCC), Cholangiocarcinoma | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04510740) |
| May 15, 2020 | NCT04389541 | Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology | iOMEDICO AG | Observational | Completed | Advanced Solid Tumors or Hematologic Malignancies | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04389541) |
| March 2, 2020 | NCT04290806 | Registry Platform Gastric/Esophageal Cancer (SAPHIR) | iOMEDICO AG | Observational | Recruiting | Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal... | 1,900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04290806) |
| April 11, 2019 | NCT03911219 | Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line... | iOMEDICO AG | Observational | Completed | Stage IV Non-small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer, Advanced (Locally Advanced and Inoperable... | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03911219) |
| January 22, 2019 | NCT03811418 | A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive... | iOMEDICO AG | Phase 3 | Withdrawn | Advanced Breast Cancer, HER2-positive Breast Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03811418) |
| August 8, 2018 | NCT03619993 | Patient Preference for Pegfilgrastim (Neulasta®) Application Forms | iOMEDICO AG | Not applicable | Completed | Non Hodgkin Lymphoma, Breast Cancer | 404 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03619993) |
| March 12, 2018 | NCT03462251 | Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line | iOMEDICO AG | Phase 3 | Completed | Breast Cancer, Hormone Receptor Positive Tumor, HER 2 Negative Breast Cancer | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03462251) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 2 | 1 |
| Phase 3 | 3 |
| Phase 4 | 3 |
| Not applicable | 1 |
| Observational | 45 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 35 |
| Recruiting | 14 |
| Active not recruiting | 3 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 10 |
| Multiple Myeloma | 8 |
| Neoplasm Metastasis | 7 |
| Carcinoma, Renal Cell | 5 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 |
| Lymphoma, Follicular | 3 |
| Lymphoma, B-Cell, Marginal Zone | 3 |
| Lymphoma, Non-Hodgkin | 3 |
| Colorectal Neoplasms | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Neoplasms | 3 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Lymphoma, Mantle-Cell | 2 |
| Waldenstrom Macroglobulinemia | 2 |
| Motor Activity | 2 |
| Cholangiocarcinoma | 2 |
| Pancreatic Neoplasms | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Anemia | 2 |
| Vomiting | 1 |
| Nausea | 1 |
| Lung Neoplasms | 1 |
| Carcinoma, Bronchogenic | 1 |
| Carcinoma, Hepatocellular | 1 |
| Small Cell Lung Carcinoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Electric utilities in the United States](https://specstream.ai/data/businesses/electric-utilities/united-states)
- [Dim sum restaurants in the United States](https://specstream.ai/data/businesses/dim-sum-restaurants/united-states)
- [Cosmetic dentistry practices in the United States](https://specstream.ai/data/businesses/cosmetic-dentistry-practices/united-states)
- [Civil rights law firms in the United States](https://specstream.ai/data/businesses/civil-rights-law-firms/united-states)
- [Cambodian restaurants in the United States](https://specstream.ai/data/businesses/cambodian-restaurants/united-states)
- [Book magazine distribution companies in the United States](https://specstream.ai/data/businesses/book-magazine-distribution-companies/united-states)
